Immunohistology of Melanocytic Neoplasms

Diagnostic Immunohistochemistry, Second Edition

Volumn , Issue , 2006, Pages 162-179

  Wick, Mark R ^a,b  

^a Surgical Pathology   (United States)

^b UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902393468     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06652-8.50012-0     Document Type: Chapter

References (199)

1. RE Nakhleh, MR Wick, A Rocamora, et al. (1990) Morphologic diversity in malignant melanomas. Am J Clin Pathol 93 731-740.
2. SS Banerjee and M Harris (2000) Morphologic and immunophenotypic variation in malignant melanoma. Histopathology 36 387-402.
3. RJ Reed and P Martin (1997) Variants of melanoma. Semin Cutan Med Surg 16 137-158.
4. H Battifora (1988) Clinical application of the immunohistochemistry of filamentous proteins. Am J Surg Pathol 12(Suppl), 24-42.
5. M Osborn (1983) Intermediate filaments as histologic markers: an overview. J Invest Dermatol 81(Suppl 1), 104s-109s.
6. FCS Ramaekers, JJ Puts, O Moesker, et al. (1983) Intermediate filaments in malignant melanomas: identification and use as a marker in surgical pathology. J Clin Invest 71 635-643.
7. J Caselitz, M Janner, E Breitbart, et al. (1983) Malignant melanomas contain only the vimentin type of intermediate filaments. Virchows Arch A 400 43-51.
8. RJ Zarbo, AM Gown, RB Nagle, et al. (1990) Anomalous cytokeratin expression in malignant melanoma: one- and two-dimensional Western blot analysis and immunohistochemical survey of 100 melanomas. Mod Pathol 3 494-502.
9. M Miettinen and K Franssila (1989) Immunohistochemical spectrum of malignant melanoma: the common presence of keratins. Lab Invest 61 623-628.
10. PE Swanson (1988) Monoclonal antibodies to human milk fat globule proteins. MR Wick, GP Siegal (Eds) Monoclonal antibodies in diagnostic immunohistochemistry New York: Dekker 227-284.
11. GS Pinkus and PJ Kurtin (1985) Epithelial membrane antigen – a diagnostic discriminant in surgical pathology. Hum Pathol 16 929-940.
12. JP Sloane and MG Ormerod (1981) Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology. Cancer 47 1786-1795.
13. WL Selby, KV Nance and KH Park (1992) Carcinoembryonic antigen – immunoreactivity in metastatic malignant melanoma. Mod Pathol 5 415-419.
14. MH Ravindranath, P Shen, N Habal, et al. (2000) Does human melanoma express carcinoembronic antigen? Anticancer Res 20 3083-3092.
15. B Ben-Izhak, R Levy, S Weill, et al. (1997) Anorectal malignant melanoma: a clinicopathology study, including immunohistochemistry and DNA flow cytometry. Cancer 79 18-25.
16. R Muraro, M Kuroki, D Wunderlich, et al. (1988) Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor associated glycoprotein-72 antigen. Cancer Res 48 4588-4596.
17. MR Wick, PE Swanson and JC Manivel (1987) Placental alkaline phosphatase-like reactivity in human tumors: an immunohistochemical study of 520 cases. Hum Pathol 18 946-954.
18. B Chorvath, L Hunakova, M Turzova, et al. (1992) Monoclonal antibodies to two adhesive cell surface antigens (CD43 and CD59) with different distribution on hematopoietic and nonhematopoietic tumor cell lines. Neoplasma 39 325-329.
19. SF Radka, DJ Charron and FM Brodsky (1986) Class II molecules of the major histocompatibility complex considered as differentiation markers. Hum Immunol 16 390-400.
20. S Carrel, A Schmidt-Kessen, JP Mach, et al. (1983) Expression of common acute lymphoblastic leukemia antigen (CALLA) on human malignant melanoma cell lines. J Immunol 130 2456-2460.
21. KW Herbold, J Zhou, JG Haggerty, et al. (1996) CD44 expression on epidermal melanocytes. J Invest Dermatol 106 1230-1235.
22. M Sarlomo-Rikala, AJ Kovatich, A Barusevicius, et al. (1998) CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11 728-734.
23. NL Pernick, M DaSilva, MD Gangi, et al. (1999) ‘Histiocytic’ markers in melanoma. Mod Pathol 12 1072-1077.
24. NE Tang, GP Luyten, CM Mooy, et al. (1996) HNK-1 antigens on uveal and cutaneous melanoma cell lines. Melanoma Res 6 411-418.
25. N Weidner and J Tjoe (1994) Immunohistochemical profile of monoclonal antibody O13. Am J Surg Pathol 18 486-494.
26. VA Tron, S Krajewski, H Klein-Parker, et al. (1995) Immunohistochemical analysis of bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 146 643-650.
27. PG Chu, DA Arber and LM Weiss (2003) Expression of T/NK-cell and plasma-cell antigens in nonhematopoietic epithelioid neoplasms: an immunohistochemical study of 447 cases. Am J Clin Pathol 120 64-70.
28. DJ Ruiter, AK Bhan, TJ Harrist, et al. (1982) Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol 129 2808-2815.
29. M Miettinen, J Chatten, A Paetan, et al. (1998) Monoclonal antibody NB84 in the differential diagnosis of neuroblastoma and other small round cell tumors. Am J Surg Pathol 22 327-332.
30. D Mezebish, K Smith, J Williams, et al. (1998) Neurocristic cutaneous hamartoma: a distinctive dermal melanocytosis with an unknown malignant potential. Mod Pathol 11 573-578.
31. PR Van Ginkel, RL Gee, TM Walker, et al. (1998) The identification and differential expression of calcium-binding proteins associated with ocular melanoma. Biochim Biophys Acta 1448 290-297.
32. SK Ludwin, JC Kosek and LF Eng (1976) The topographical distribution of S100 protein and GFA protein in the adult rat brain: an immunohistochemical study using horseradish peroxidase-labeled antibodies. J Comp Neurol 165 197-208.
33. R Gaynor, R Irie, D Morton, et al. (1981) S100 protein: a marker for human malignant melanomas? Lancet 1 869-871.
34. J Baudier, C Briving, J Deinum, et al. (1982) Effect of S100 protein and calmodulin on calcium-induced disassembly of brain microtubule proteins in vitro. FEBS Lett 147 165-168.
35. K Stefansson, R Wollmann and M Jerkovic (1982) S100 protein in soft tissue tumors derived from Schwann cells and melanocytes. Am J Pathol 106 261-268.
36. K Takahashi, T Isobe, Y Ohtsuki, et al. (1984) Immunohistochemical study on the distribution of alpha and beta subunits of S100 protein in human normal and neoplastic tissues. Virchows Arch B 45 385-396.
37. GA Herrera, JR Pena, EA Turbat-Herrera, et al. (1994) The diagnosis of melanoma: current approaches addressing tumor differentiation. Pathol Annu 29(Part 1), 233-260.
38. SC Loeffel, GY Gillespie, SA Mirmiram, et al. (1985) Cellular immunolocalization of S100 protein within fixed tissue sections by monoclonal antibodies. Arch Pathol Lab Med 109 117-122.
39. BR Smoller (1994) Immunohistochemistry in the diagnosis of melanocytic neoplasms. Pathol State Art Rev 2 371-383.
40. LG Kindblom, P Lodding, L Rosengren, et al. (1984) S100 protein in melanocytic tumors. Acta Pathol Microbiol Scand 92 219-230.
41. T Nakajima, S Watanabe, Y Sato, et al. (1982) An immunoperoxidase study of S100 protein distribution in normal and neoplastic tissues. Am J Surg Pathol 7 715-727.
42. AJ Cochran, HF Lu, PX Li, et al. (1993) S100 protein remains a practical marker for melanocytic and other tumors. Melanoma Res 3 325-330.
43. PE Swanson and MR Wick (1993) Immunohistochemistry of cutaneous tumors. Applied immunohistochemistry for the surgical pathologist Cambridge, UK: Edward Arnold 269-308.
44. A Ribe and NS McNutt (2003) S100A6 protein expression is different in Spitz nevi and melanomas. Mod Pathol 16 505-511.
45. J Rogers, M Khan and J Ellis (1990) Calretinin and other calcium binding proteins in the nervous system. Adv Exp Med Biol 269 195-203.
46. AP Tos and C Doglioni (1998) Calretinin: a novel tool for diagnostic immunohistochemistry. Adv Anat Pathol 5 61-66.
47. E Schulze, M Witt, T Fink, et al. (1997) Immunohistochemical detection of human skin nerve fibers. Acta Histochem 99 301-309.
48. V Gotzos, ES Wintergerst, JP Musy, et al. (1999) Selective distribution of calretinin in adenocarcinomas of the human colon and adjacent tissues. Am J Surg Pathol 23 701-711.
49. KV Nance and GP Siegal (1988) The use of monoclonal antibodies in the search for tumor-specific antigens. MR Wick, GP Siegal (Eds) Monoclonal antibodies in diagnostic immunohistochemistry New York: Dekker 593-622.
50. IM Shih, M Nesbit, M Herlyn, et al. (1998) A new MEL-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue. Mod Pathol 11 1098-1106.
51. U Trefzer, N Rietz, Y Chen, et al. (2000) SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch Dermatol Res 292 583-589.
52. N Brouwenstijn, EH Slager, AB Bakker, et al. (1997) Transcription of the gene encoding melanoma-associated antigen gp10 tissues and cell lines other than those of the melanocytic lineage. Br J Cancer 76 1562-1566.
53. GJ Adema, AJ deBoer, AM Vogel, et al. (1994) Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem 269 20126-20133.
54. GJ Adema, AB Bakker, J deBoer, et al. (1996) PMel17 is recognized by monoclonal antibodies NKI-beteb, HMB-45, HMB-50, and by anti-melanoma cytotoxic T-cells. Br J Cancer 73 1044-1048.
55. Y Kawakami, MI Nishimura, NP Restifo, et al. (1993) T-cell recognition of human melanoma antigens. J Immunother 14 88-93.
56. YT Chen, E Stockert, A Jungbluth, et al. (1996) Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 93 5916-5919.
57. Y Kawakami, JK Battles, T Kobayashi, et al. (1997) Production of recombinant MART-1 proteins and specific anti-MART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J Immunol Methods 202 13-25.
58. T Kageshita, Y Kawakami, S Hirai, et al. (1997) Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother 20 460-465.
59. MR Nicotra, P Nistico, A Mangoni, et al. (1997) Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas. J Immunother 20 466-469.
60. C Pierard-Franchimont, C Letawe, AF Nikkels, et al. (1998) Patterns of the immunohistochemical expression of melanoma-associated antigens and density of CD45R0+ activated T-lymphocytes and L1-protein-positive macrophages in primary cutaneous melanomas. Int J Mol Med 2 721-724.
61. PA Fetsch, FM Marincola, A Filie, et al. (1999) Melanoma-associated antigen recognized by T-cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine needle aspiration. Cancer 87 37-42.
62. KJ Busam and AA Jungbluth (1999) Melan-A, a new melanocytic differentiation marker. Adv Anat Pathol 6 12-18.
63. Z Orosz (1999) Melan-A/MART-1 expression in various melanocytic lesions and in nonmelanocytic soft tissue tumors. Histopathology 34 517-525.
64. LL Yu, TJ Flotte, KK Tanabe, et al. (1999) Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 86 617-627.
65. A Anichini, A Molla, R Mortarini, et al. (1999) An expanded peripheral T-cell population to a cytotoxic T-lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 190 651-667.
66. R Bergman, H Azzam, E Sprecher, et al. (2000) A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas. J Am Acad Dermatol 42 496-500.
67. S Heegaard, OA Jensen and JU Prause (2000) Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against Melan-A with S100 protein and HMB-45. Melanoma Res 10 350-354.
68. GJ Adema, AJ deBoer, R VantHullenaar, et al. (1993) Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol 143 1579-1585.
69. AM Chiamenti, F Vella, F Bonetti, et al. (1996) Anti-melanoma monoclonal antibody HMB-45 on enhanced chemi-luminescence-Western blotting recognizes a 30–35 kDa melanosome-associated sialated glycoprotein. Melanoma Res 6 291-298.
70. RM Esclamado, AM Gown and AM Vogel (1986) Unique proteins defined by monoclonal antibodies specific for human melanoma. Am J Surg 152 376-385.
71. AM Gown, AM Vogel, DH Hoak, et al. (1986) Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 123 195-203.
72. G Schaumburg-Lever, G Metzler and E Kaiserling (1991) Ultrastructural localization of HMB-45 binding sites. J Cutan Pathol 18 432-435.
73. JP Palazzo and PH Duray (1988) Congenital agminated Spitz nevi: immunoreactivity with a melanoma-associated monoclonal antibody. J Cutan Pathol 15 166-170.
74. BR Smoller, NS McNutt and A Hsu (1989) HMB-45 staining of dysplastic nevi: support for a spectrum of progression toward melanoma. Am J Surg Pathol 13 680-684.
75. HG Skelton III, KJ Smith, TL Barrett, et al. (1991) HMB-45 staining in benign and malignant melanocytic lesions: a reflection of cellular activation. Am J Dermatopathol 131 543-550.
76. MR Wick (1991) HMB-45: a clue to the biology of malignant melanoma? J Cutan Pathol 18 307-308.
77. BR Smoller, A Hsu and J Krueger (1991) HMB-45 monoclonal antibody recognizes an inducible and reversible melanocyte cytoplasmic protein. J Cutan Pathol 18 315-322.
78. MR Wick, PE Swanson and A Rocamora (1988) Recognition of malignant melanoma by monoclonal antibody HMB-45: an immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol 15 201-207.
79. K Blessing, DS Sanders and JJ Grant (1998) Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology 32 139-146.
80. AM Vogel and RM Esclamado (1988) Identification of a secreted Mr 95,000 glycoprotein in human melanocytes and melanomas by a melanocyte specific monoclonal antibody. Cancer Res 48 1286-1294.
81. RY Kim and GJ Wistow (1992) The cDNA RPE1 and monoclonal antibody HMB-50 define gene products preferentially expressed in retinal pigment epithelium. Exp Eye Res 55 657-662.
82. H Bar and W Schlote (1997) Malignant melanoma in the CNS: subtyping and immunocytochemistry. Clin Neuropathol 16 337-345.
83. AW Barrett, JH Bennett and PM Speight (1995) A clinicopathological and immunohistochemical analysis of primary oral mucosal melanoma. Eur J Cancer B Oral Oncol 31B 100-105.
84. SS Fernando, S Johnson and J Bate (1994) Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S100 protein, HMB-45 monoclonal antibody, and NKI/C3 monoclonal antibody. Pathology 26 16-19.
85. PW Bishop, LP Menasce, AJ Yates, et al. (1993) An immunophenotypic survey of malignant melanomas. Histopathology 23 159-166.
86. RM Mackie, I Campbell and M Turbitt (1984) Use of NKI/C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions. J Clin Pathol 37 367-372.
87. H Yaziji and AM Gown (2003) Immunohistochemical markers of melanocytic tumors. Int J Surg Pathol 11 11-15.
88. J Mangini, N Li and J Bhawan (2002) Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness. Am J Dermatopathol 24 270-281.
89. HD Friedman and AH Tatum (1991) HMB-45 positive malignant lymphoma: a case report with literature review of aberrant HMB-45 reactivity. Arch Pathol Lab Med 115 826-830.
90. C Hancock, BC Allen and GA Herrera (1991) HMB-45 detection in adenocarcinomas. Arch Pathol Lab Med 115 886-890.
91. PD Unger, K Hoffman, SN Thung, et al. (1992) HMB-45 reactivity in adrenal pheochromocytomas. Arch Pathol Lab Med 116 151-153.
92. CM Zimmer, J Gottschalk, S Goebel, et al. (1992) Melanoma-associated antigens in tumors of the nervous system: an immunohistochemical study with the monoclonal antibody HMB-45. Virchows Arch A 420 121-126.
93. JN Eble, MB Amin and RH Young (1997) Epithelioid angiomyolipoma of the kidney: a report of five cases with prominent and diagnostically confusing epithelioid smooth muscle component. Am J Surg Pathol 21 1123-1130.
94. PA Fetsch, JF Fetsch, FM Marincola, et al. (1998) Comparison of melanoma antigen recognized by T-cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor. Mod Pathol 11 699-703.
95. T Ribalta, J Lloreta, A Munne, et al. (2000) Malignant pigmented clear cell epithelioid tumor of the kidney: clear cell (‘sugar’) tumor versus malignant melanoma. Hum Pathol 31 516-519.
96. G Zamboni, M Pea, G Martignoni, et al. (1996) Clear cell ‘sugar’ tumor of the pancreas: a novel member of the family of lesions characterized by the presence of perivascular epithelioid cells. Am J Surg Pathol 20 722-730.
97. F Bonetti, M Pea, G Martignoni, et al. (1994) Clear cell (‘sugar’) tumor of the lung is a lesion strictly related to angiomyolipoma – the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC). Pathology 26 230-236.
98. Y Tanaka, R Ijiri, K Kato, et al. (2000) HMB-45/Melan-A and smooth muscle actin-positive clear-cell epithelioid tumor arising in the ligamentum teres hepatis: additional example of clear-cell ‘sugar’ tumors. Am J Surg Pathol 24 1295-1299.
99. MJ Gaffey, SE Mills, RJ Zarbo, et al. (1991) Clear cell tumor of the lung: immunohistochemical and ultrastructural evidence of melanogenesis. Am J Surg Pathol 15 644-653.
100. KJ Busam, K Iversen, KA Coplan, et al. (1998) Immunoreactivity for A103, an antibody to melan-A (MART-1) in adrenocortical and other steroid tumors. Am J Surg Pathol 22 57-63.
101. AB Lerner and TB Fitzpatrick (1950) Biochemistry of melanin formation. Physiol Rev 30 91-126.
102. TB Fitzpatrick, M Miyomato and K Iskikawa (1967) The evolution of concepts of melanin biology. Arch Dermatol 96 305-323.
103. D Pellegrino, CR Bellina, G Manca, et al. (2000) Detection of melanoma cells in peripheral blood and sentinel lymph nodes by RT-PCR analysis: a comparative study with immunohistochemistry. Tumori 86 336-338.
104. GE Orchard (2000) Comparison of immunohistochemical labeling of melanocyte differentiation antibodies melan-A, tyrosinase, and HMB-45 with NKI/C3 and S100 protein in the evaluation of benign nevi and malignant melanoma. Histochem J 32 475-481.
105. AA Jungbluth, K Iversen, K Coplan, et al. (2000) T311 – an antityrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathol Res Pract 196 235-242.
106. TJ DeVries, D Trancikova, DJ Ruiter, et al. (1998) High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase, and TRP-1 in uveal melanoma. Br J Cancer 78 1156-1161.
107. O Kaufmann, S Koch, J Burghardt, et al. (1998) Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol 11 740-746.
108. HJ Blaheta, B Schittek, H Breuninger, et al. (1998) Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry. Int J Cancer 79 318-323.
109. JN Cormier, A Abati, P Fetsch, et al. (1998) Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother 21 27-31.
110. N Sato, S Suzuki, H Takimoto, et al. (1996) Monoclonal antibody MAT-1 against human tyrosinase can detect melanogenic cells on formalin-fixed paraffin-embedded sections. Pigment Cell Res 9 72-76.
111. H Takimoto, S Suzuki, S Masui, et al. (1995) MAT-1, a monoclonal antibody that specifically recognizes human tyrosinase. J Invest Dermatol 105 764-768.
112. YT Chen, E Stockert, S Tsang, et al. (1995) Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 92 8125-8129.
113. KS Clarkson, IC Sturdgess and AJ Molyneux (2001) The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: comparison of the novel T311 antibody (antityrosinase) with S100, HMB-45, and A103 (MART-1; Melan-A). J Clin Pathol 54 196-200.
114. K Takeda, K Yasumoto, R Takada, et al. (2000) Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J Biol Chem 275 14013-14016.
115. J Vachtenheim and H Novotna (1999) Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas. Cell Mol Biol 45 1075-1082.
116. MD Galibert, U Yavuzer, TJ Dexter, et al. (1999) Pax3 and regulation of the melanocyte-specific tyrosinase-related protein-1 promoter. J Biol Chem 274 26894-26900.
117. C Verastegui, C Bertolotto, K Bille, et al. (2000) TFE3, a transcription factor homologous to microphthalmia, is a potential transcriptional activator of tyrosinase and TyrpI genes. Mol Endocrinol 14 449-456.
118. MB Koch, IM Shih, SW Weiss, et al. (2001) Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle-cell melanoma from morphologic mimics. Am J Surg Pathol 25 58-64.
119. R King, PB Googe, KN Weilbaecher, et al. (2001) Microphthalmia transcription factor expression in cutaneous benign and malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol 25 51-57.
120. R King, KN Weilbaecher, G McGill, et al. (1999) Microphthalmia transcription factor: a sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol 155 731-738.
121. M Miettinen, M Fernandez, K Franssila, et al. (2001) Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol 25 205-211.
122. A Zavala-Pompa, AL Folpe, RE Jimenez, et al. (2001) Immunohistochemical study of microphthalmia transcription factor and tyrosinase in angiomyolipoma of the kidney, renal cell carcinoma, and retroperitoneal sarcomas: comparative evaluation with traditional diagnostic markers. Am J Surg Pathol 25 65-70.
123. AL Folpe, ZD Goodman, KG Ishak, et al. (2000) Clear cell myomelanocytic tumor of the falciform ligament/ligamentum teres: a novel member of the perivascular epithelioid cell family of tumors with a predilection for children and young adults. Am J Surg Pathol 24 1239-1246.
124. P Rochaix, M Lacroix-Triki, L Lamant, et al. (2003) PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen. Mod Pathol 16 481-490.
125. KJ Busam (2004) The use and application of special techniques in assessing melanocytic tumors. Pathology 36 462-469.
126. KJ Busam, D Kucukgol, E Sato, et al. (2005) Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers. Am J Surg Pathol 29 400-406.
127. MR Wick, SJ Stanley and PE Swanson (1988) Immunohistochemical diagnosis of sinonasal melanoma, carcinoma, and neuroblastoma with monoclonal antibodies HMB-45 and anti-synaptophysin. Arch Pathol Lab Med 112 616-620.
128. DW Franquemont and SE Mills (1991) Sinonasal malignant melanoma: a clinicopathologic and immunohistochemical study of 14 cases. Am J Clin Pathol 96 689-697.
129. B Wiedenmann, WW Franke, C Kuhn, et al. (1986) Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA 83 3500-3504.
130. RV Lloyd and BS Wilson (1983) Specific endocrine tissue marker defined by a monoclonal antibody. Science 222 628-630.
131. GJ Kontochristopoulos, PG Stavropoulos, K Krasagakis, et al. (2000) Differentiation between Merkel cell carcinoma and malignant melanoma: an immunohistochemical study. Dermatology 201 123-126.
132. KM Klemm, CA Moran and S Suster (1999) Pigmented thymic carcinoids: a clinicopathological and immunohistochemical study of two cases. Mod Pathol 12 946-948.
133. AA Gal, MN Koss, L Hochholzer, et al. (1993) Pigmented pulmonary carcinoid tumor: an immunohistochemical and ultrastructural study. Arch Pathol Lab Med 117 832-836.
134. CA Moran, J Albores-Saavedra, BM Wenig, et al. (1997) Pigmented extraadrenal paragangliomas: a clinicopathologic and immunohistochemical study of five cases. Cancer 79 398-402.
135. G Pettinato, JC Manivel, ESG d'Amore, et al. (1991) Melanotic neuroectodermal tumor of infancy: a reexamination of a histogenetic problem based on immunohistochemical, flow cytometric, and ultrastructural study of 10 cases. Am J Surg Pathol 15 233-245.
136. SB Kapadia, DM Frisman, CL Hitchcock, et al. (1993) Melanotic neuroectodermal tumor of infancy: clinicopathological, immunohistochemical, and flow cytometric study. Am J Surg Pathol 17 566-573.
137. RP Mennemeyer, KO Hallman, SP Hammar, et al. (1979) Melanotic schwannoma: clinical and ultrastructural studies of three cases with evidence of intracellular melanin synthesis. Am J Surg Pathol 3 3-10.
138. GE Orchard and E Wilson-Jones (1994) Immunocytochemistry in the diagnosis of malignant melanoma. Br J Biomed Sci 51 44-56.
139. DR Springall, J Gu, D Cocchia, et al. (1983) The value of S100 immunostaining as a diagnostic tool in human malignant melanomas: a comparison using S100 and neuron-specific enolase antibodies. Virchows Arch A 400 331-343.
140. AP Dhillon, J Rode and A Leathem (1982) Neuron-specific enolase: an aid to the diagnosis of melanoma and neuroblastoma. Histopathology 6 81-92.
141. JA Reed, B Finnerty and AP Albino (1999) Divergent cellular differentiation pathways during the invasive stage of cutaneous malignant melanoma progression. Am J Pathol 155 549-555.
142. OP Sangueza and L Requena (1998) Neoplasms with neural differentiation: a review. Part II: Malignant neoplasms. Am J Dermatopathol 20 89-102.
143. CM Mooy, GP Luyten, PT DeJong, et al. (1995) Neural cell adhesion molecule distribution in primary and metastatic uveal melanomas. Hum Pathol 26 1185-1190.
144. AJ Cochran, A Roberts, DR Wen, et al. (2004) Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumors. Pathology 36 478-484.
145. VG Prieto and SH Clark (2002) Processing of sentinel lymph nodes for detection of metastatic melanoma. Ann Diagn Pathol 6 257-264.
146. K Spanknebel, DG Coit, SC Bieligk, et al. (2005) Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol 29 305-317.
147. VB Shidham, R Komorowski, V Macias, et al. (2004) Optimization of an immunostaining protocol for the rapid intraoperative evaluation of melanoma sentinel lymph node imprint smears with the ‘MCW melanoma cocktail.’. Cytojournal 1 2.
148. N Medalie and AB Ackerman (2004) Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma: an assertion based on comprehensive, critical analysis 2nd edn New York: Ardor Scribendi Press 1-95.
149. HN Abrahamsen, SJ Hamilton-Dutoit, J Larsen, et al. (2004) Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. Cancer 100 1683-1691.
150. MR Wick (1998) Prognostic factors for cutaneous melanoma. Am J Clin Pathol 110 713-718.
151. S Moretti, A Spallanzani, A Chiarugi, et al. (2001) Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. J Am Acad Dermatol 44 188-192.
152. VA Florenes, RS Faye, GM Maelandsmo, et al. (2000) Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin expression is associated with poor clinical outcome in superficial melanomas. Clin Cancer Res 6 3614-3620.
153. O Straume, L Sviland and LA Akslen (2000) Loss of nuclear p16 protein expression correlates with increased tumor proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 6 1845-1853.
154. Z Kaleem, AC Lind, PA Humphrey, et al. (2000) Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas? Mod Pathol 13 217-222.
155. R Henrique, R Azevedo, MJ Bento, et al. (2000) Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. J Am Acad Dermatol 43 991-1000.
156. VA Florenes, GM Maelandsmo, R Holm, et al. (2004) Expression of activated Trk-A protein in melanocytic tumors: relationship to cell proliferation and clinical outcome. Am J Clin Pathol 122 412-420.
157. CH Graham, J Rivers, RS Kerbel, et al. (1994) Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am J Pathol 145 510-514.
158. T Vlaykova, L Talve, M Hahka-Kemppinen, et al. (1999) MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma. Oncology 57 242-252.
159. RS Kerbel, H Kobayashi, CH Graham, et al. (1996) Analysis and significance of the malignant ‘eclipse’ during the progression of primary cutaneous human melanomas. J Invest Dermatol Symp Proc 1 183-187.
160. M Gutman, RK Singh, R Radinsky, et al. (1994) Intertumoral heterogeneity of receptor-tyrosinase kinase expression in human melanoma cell lines with metastatic capabilities. Anticancer Res 14 1759-1765.
161. D Elder (1999) Tumor progression, early diagnosis, and prognosis of melanoma. Acta Oncol 38 535-547.
162. T Nagasaka, R Lai, LJ Medeiros, et al. (1999) Cyclin D1 over-expression in Spitz nevi: an immunohistochemical study. Am J Dermatopathol 21 115-120.
163. L Kanter-Lewensohn, MA Hedblad, J Wedje, et al. (1997) Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas. Mod Pathol 10 917-920.
164. R Bergman, A Shemer, R Levy, et al. (1995) Immunohistochemical study of p53 protein expression in Spitz nevi as compared with other melanocytic tumors. Am J Dermatopathol 17 547-550.
165. NS Penneys, E Seigfried, G Nahass, et al. (1995) Expression of proliferating cell nuclear antigen in Spitz nevus. J Am Acad Dermatol 32 964-967.
166. H Takahashi, K Maeda, K Maeda, et al. (1987) Immunohistochemical characterization of Spitz's nevus: differentiation from common melanocytic nevi, dysplastic melanocytic nevus, and malignant melanoma. J Dermatol 14 533-541.
167. EJ Glusac and JM McNiff (1999) Epithelioid cell histiocytoma: a simulant of vascular and melanocytic neoplasms. Am J Dermatopathol 21 1-7.
168. KJ Busam, SR Granter, K Iversen, et al. (2000) Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi. Am J Dermatopathol 22 237-241.
169. KJ Busam, J Rosai, K Iversen, et al. (2000) Xanthogranulomas with inconspicuous foam cells and giant cells mimicking malignant melanoma: a clinical, histologic, and immunohistochemical study of three cases. Am J Surg Pathol 24 864-869.
170. CK Ma, RJ Zarbo and AM Gown (1992) Immunohistochemical characterization of atypical fibroxanthoma and dermato-fibrosarcoma protuberans. Am J Clin Pathol 97 478-483.
171. C Diaz-Cascajo, S Borghi and M Bonczkowitz (1998) Pigmented atypical fibroxanthoma. Histopathology 33 537-541.
172. A Gloghini, A Rizzo, I Zanette, et al. (1995) KP1/CD68 expression in malignant neoplasms including lymphomas, sarcomas, and carcinomas. Am J Clin Pathol 103 425-431.
173. S Suster (1999) Tumors of the skin composed of large cells with abundant eosinophilic cytoplasm. Semin Diagn Pathol 16 162-177.
174. BT Borek, PH McKee, JA Freeman, et al. (1998) Primary malignant melanoma with rhabdoid features: a histologic and immunocytochemical study of two cases. Am J Dermatopathol 20 123-127.
175. WB Laskin, DR Knittel and JN Frame (1995) S100 protein and HMB-45-negative ‘rhabdoid’ malignant melanoma: a totally dedifferentiated malignant melanoma? Am J Clin Pathol 103 772-773.
176. A Anstey, R Cerio, N Ramnarain, et al. (1994) Desmoplastic malignant melanoma: an immunocytochemical study of 25 cases. Am J Dermatopathol 16 14-22.
177. KC Gatter, K Alcock, A Heryet, et al. (1984) The differential diagnosis of routinely-processed anaplastic tumors using monoclonal antibodies. Am J Clin Pathol 82 33-43.
178. JG Strickler, SA Michie, RA Warnke, et al. (1986) The ‘syncytial’ variant of nodular sclerosing Hodgkin's disease. Am J Surg Pathol 10 470-477.
179. JH Ritter, SE Mills, MJ Gaffey, et al. (1997) Clear cell tumors of the alimentary tract and abdominal cavity. Semin Diagn Pathol 14 213-219.
180. NG Ordonez (1999) Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 112 75-89.
181. H Mizutani, S Ohyanagi, T Hayashi, et al. (1996) Functional thrombomodulin expression on epithelial skin tumors as a differentiation marker for suprabasal keratinocytes. Br J Dermatol 135 187-193.
182. H Battifora and EG Silva (1986) The use of antikeratin antibodies in the immunohistochemical distinction between neuroendocrine (Merkel cell) carcinoma of the skin, lymphoma, and oat cell carcinoma. Cancer 58 1040-1046.
183. HB Clark (1984) Immunohistochemistry of nervous system antigens: diagnostic applications in surgical neuropathology. Semin Diagn Pathol 1 309-316.
184. C Zimmer, J Gottschalk, S Goebel, et al. (1992) Melanoma-associated antigens in tumors of the nervous system: an immunohistochemical study with monoclonal antibody HMB-45. Virchows Arch A 420 121-126.
185. J Gottschalk, G Jautzke and C Schreiner (1992) Epithelial and melanoma antigens in gliosarcoma: an immunohistochemical study. Pathol Res Pract 188 182-190.
186. P Lodding, LG Kindblom and L Angervall (1990) Metastases of malignant melanoma simulating soft tissue sarcoma: a clinicopathological, light- and electron microscopic and immunohistochemical study of 21 cases. Virchows Arch A 417 377-388.
187. SS Banerjee, JD Coyne, LP Menasce, et al. (1998) Diagnostic lessons of mucosal melanoma with osteocartilaginous differentiation. Histopathology 33 255-260.
188. PE Swanson and MR Wick (1989) Clear cell sarcoma: an immunohistochemical analysis of six cases and comparison with other epithelioid neoplasms of soft tissue. Arch Pathol Lab Med 113 55-60.
189. G Mechtersheimer, W Tilgen, E Klar, et al. (1989) Clear cell sarcoma of tendons and aponeuroses: case presentation with special reference to immunohistochemical findings. Hum Pathol 20 914-917.
190. MM Almeida, AM Nunes and WJ Frable (1994) Malignant melanoma of soft tissue: a report of three cases with diagnosis by fine needle aspiration cytology. Acta Cytol 38 241-246.
191. G Stenman, LG Kindblom and L Angervall (1992) Reciprocal translocation t(12;22)(q13;q13) in clear-cell sarcoma of tendons and aponeuroses. Genes Chromosomes Cancer 4 122-127.
192. SM Langezaal, JF Graadt van Roggen, AM Gleton-Jansen, et al. (2001) Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts). Br J Cancer 84 535-538.
193. AL Folpe, CE Hill, DM Parham, et al. (2000) Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol 24 1657-1662.
194. JL Winters, JD Geil and WN O'Connor (1995) Immunohistology, cytogenetics, and molecular studies of small round cell tumors of childhood: a review. Ann Clin Lab Sci 25 66-78.
195. PE Swanson, BW Scheithauer and MR Wick (1995) Peripheral nerve sheath neoplasms: clinicopathologic and immunochemical observations. Pathol Annu 30(Pt. 2), 1-82.
196. MR Wick (1990) Malignant peripheral nerve sheath tumors of the skin. Mayo Clin Proc 65 279-282.
197. LE Shabrawi-Caelen, H Kerl and L Cerroni (2004) Melan-A: not a helpful marker in distinction between melanoma in-situ on sun-damaged skin and pigmented actinic keratosis. Am J Dermatopathol 26 364-366.
198. MD Herron, SL Vanderhoof, K Smock, et al. (2004) Proliferative nodules in congenital melanocytic nevi: a clinicopathologic and immunohistochemical analysis. Am J Surg Pathol 28 1017-1025.
199. PM Guerriere-Kovach, EL Hunt, JW Patterson, et al. (2004) Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Am J Clin Pathol 122 70-77.